Axa S.A. Aeglea Bio Therapeutics, Inc. Transaction History

Axa S.A.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 13, 2022	SELL	$1.87 - $4.77 $832,020 - $2.12 Million	-444,931 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$3.5 - $8.42 $18,424 - $44,322	5,264 Added 1.2%	444,931 $2.11 Million
Q3 2021 Nov 15, 2021	BUY	$6.03 - $7.95 $92,349 - $121,754	15,315 Added 3.61%	439,667 $3.5 Million
Q2 2021 Aug 13, 2021	BUY	$6.32 - $8.38 $2,730 - $3,620	432 Added 0.1%	424,352 $2.95 Million
Q1 2021 May 14, 2021	BUY	$6.76 - $8.57 $67,133 - $85,108	9,931 Added 2.4%	423,920 $3.36 Million
Q4 2020 Feb 12, 2021	BUY	$7.02 - $9.83 $764,204 - $1.07 Million	108,861 Added 35.68%	413,989 $3.26 Million
Q3 2020 Nov 13, 2020	BUY	$6.51 - $9.33 $1.99 Million - $2.85 Million	305,128 New	305,128 $2.16 Million

241K

Ticker AGLE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 61,172,500
Market Cap $1.69B
Description
Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients and families with rare metabolic diseases. The company's lead product candidate is pegzilarginase, a recombinant human Arginase 1 that is in Phase III PEACE trial to evaluate the safety and efficacy f...

Get notified when there are updates to the investment portfolio of Axa S.A., based on Form 13F filings with the SEC.

Stay updated on Axa S.A. with notifications on news.